Madison, WI, United States
Madison, WI, United States

Time filter

Source Type

News Article | December 8, 2016
Site: www.prnewswire.co.uk

European and U.S. Hospitals Advance Adaptive Cancer Care with Image-Guided Radiation Therapy System Accuray Incorporated (NASDAQ: ARAY) announced today that leading hospitals in Europe and the United States are now treating patients with the new Radixact™ Treatment Delivery System, fully integrated with the new Accuray Precision™ Treatment Planning System and iDMS™ Data Management System. The first patient treatment in the world was administered at the University Hospital Brussels (UZ Brussel) in Belgium and in the United States at Froedtert & the Medical College of Wisconsin Froedtert Hospital in Milwaukee, Wisconsin, part of the Froedtert & MCW Cancer Network. The University Hospital Brussels (UZ Brussel) continues its legacy of innovation with the installation of the Radixact System, software, and treatment of the first patient worldwide. The smart new radiation therapy system represents the next generation in TomoTherapy® treatment delivery, significantly increasing treatment speed and ease of use. It enables clinicians to treat a wide range of cancer cases, from routine to complex, with precision and increased efficiency. "We are proud and excited to be the first hospital in the world to offer the new Radixact treatment option to our patients here in Brussels. This advanced technology represents another step forward toward optimal cancer care and improved quality of life for patients," said Prof. Mark De Ridder, Head of the Radiation Oncology Department, University Hospital Brussels (UZ Brussel, Vrije Universiteit Brussel). "The first patient who underwent a Radixact procedure received radiation to treat a metastatic mass in the neck. We are now actively treating patients across a broad range of cases and all treatments have gone smoothly. The precision software is straightforward, the image quality on the system is improved and dose delivery is efficient." Additionally, patients in France will have access to the Radixact System with its recent installation at the IUCT Oncopole - Institut Universitaire du Cancer de Toulouse in Toulouse, France. The hospital's clinical experts use the most current advances in cancer treatments to develop personalized programs which improve the quality of care they provide to patients. The Radixact System in the United States Multiple sites in the United States are now equipped with the Radixact System. Miami Cancer Institute, a part of Baptist Health South Florida, and Froedtert & MCW Cancer Network are the first to install the system. Froedtert Hospital treated the first patient in the United States and is the only cancer program in the Midwest currently offering treatment with the advanced Radixact platform. Froedtert and MCW physicians selected this system because it expands cancer treatment capabilities to improve patients' outcomes and quality of life. "For more than a decade, the Froedtert & MCW Cancer Network has been at the forefront of the evolution of image-guided and adaptive radiation therapy with the goal of providing more personalized treatments," said Christopher Schultz, MD, FACR, Medical College of Wisconsin Professor and Chairman of the Department of Radiation Oncology with the Froedtert & MCW Cancer Network. "The new Radixact™ platform tightly integrates the treatment planning function with the delivery of image-guided, highly conformal treatments and importantly, provides the tools to perform plan adaption when necessary." The Radixact System was also chosen as the newest approach in advanced radiation therapy treatment for the new state-of-the-art $430 million facility at Miami Cancer Institute. "Being the first in the Southeast to offer this sophisticated technology helps to further expand the comprehensive radiation treatments available to Miami Cancer Institute's patient population, giving our unique and integrated department the opportunity to deliver therapies best suited to treat a wide variety of cancers," said Minesh P. Mehta, M.D., Deputy Director and Chief of Radiation Oncology at Miami Cancer Institute. The Radixact® System leverages the TomoTherapy® System's efficient, daily low-dose fan beam MVCT image guidance and unique ring gantry architecture to deliver precise radiation treatments for more patients, every day. "We are excited about the early momentum in the adoption of this new radiation therapy platform. Our customers have already treated patients with the Radixact System, demonstrating their confidence in its value as a mainstream treatment option," said Joshua H. Levine, president and chief executive officer of Accuray. "These early adopters are leading the way for other hospitals and clinics seeking an innovative and effective technology to help them provide best-in-class radiation treatments for their cancer patients now and into the future." For further information on the Radixact System, visit http://www.accuray.com . For Important Safety Information please refer to http://www.accuray.com/safety-statement-radiation-treatment Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit http://www.accuray.com. Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, market acceptance of our new technologies, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 24, 2016, the company's report on Form 10-Q, filed on November 1, 2016, and as updated periodically with the company's other filings with the SEC. Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.


News Article | December 21, 2016
Site: en.prnasia.com

SUNNYVALE, Calif., Dec. 21, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) has signed an agreement with Hong Kong Sanatorium & Hospital (HKSH) for the acquisition of three Radixact™ Systems that will provide clinicians and their patients with access to the newest advanced radiation therapy. Of the three Radixact Systems, two will replace existing TomoTherapy® Systems and one will be installed in a new bunker. The agreement also includes an upgrade of HKSH's existing CyberKnife® M6™ System to include the latest features for motion management and treatment efficiency, and was entered into backlog during Accuray's second fiscal quarter which ends December 31, 2016. The agreement with HKSH will make Radixact, the next-generation helical radiation therapy technology, available for the full range of cancer patients being treated at this private hospital system known for high quality patient care based on advanced knowledge, expertise and technology.  The system will enable the HKSH clinical team to more efficiently and effectively deliver precise radiation treatments, and to confidently adapt therapy to changes in tumor size, shape and location -- as well as subtle changes in the location of organs and other healthy tissue. "HKSH has a well-earned reputation for high-quality patient care based on advanced knowledge, expertise and technology. We are honored to expand Accuray's role in helping their team meet the needs of their rapidly growing patient population.  HKSH will be the first hospital in Asia to have both the Radixact and CyberKnife M6 Systems available for patient treatments.  This commitment shows confidence in our new Radixact System and in the Accuray team's ability to help the Hospital provide 'Quality in Service; Excellence in Care,'" said Josh Levine, President and Chief Executive Officer of Accuray. "We are excited to build on the previous experience we have had with the TomoTherapy platform by moving to the next generation helical platform from Accuray.  The TomoTherapy platform has enabled us to treat a wide range of cancer patients.  The CyberKnife M6 and Radixact Systems, together, are complementary technologies that will enable us to offer each cancer patient the advanced radiation therapy best suited to precisely treating their disease while minimizing side effects," said Mr. Wyman Li, Manager (Administration) of HKSH. "Hong Kong Sanatorium & Hospital has had great success in the treatment of cancer, the No. 1 cause of death in Hong Kong.  We are excited to build on our initial work with Accuray to offer state-of-the-art advanced radiation treatments to patients.  The Radixact and CyberKnife M6 Systems' unique modalities and precision will enable us to meet growing demand for high quality treatment and will play a key role in the armamentarium of state-of-the art technologies that form the backbone of the Hospital's arsenal against cancer," he added. For more information about the Accuray radiation therapy systems, visit www.accuray.com. For Important Safety Information please refer to http://www.accuray.com/safety-statement-radiation-treatment Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com. Hong Kong Sanatorium & Hospital (HKSH) is one of the leading private hospitals in Hong Kong.  It is owned by the Li Shu Fan Medical foundation (LSFMF).  HKSH is committed to fulfilling LSFMF's vision of providing quality health care and advancing medical education and research, with an overriding concern for the public good. Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, market acceptance of our new technologies, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 24, 2016, the company's report on Form 10-Q, filed on November 1, 2016, and as updated periodically with the company's other filings with the SEC. Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.


Practice-Changing Study Presented at the 2016 Best of ASTRO Meeting Accuray Incorporated (NASDAQ: ARAY) announced today new data showing that 80 percent of patients with solitary plasmacytoma of the bone (SPB) had excellent cancer control four years after receiving intensity-modulated radiation therapy (IMRT) delivered with the TomoTherapy® System, in addition to immunomodulatory drugs (IMiDs) or proteasome inhibitors (PI).[1] The concurrent treatments were well-tolerated and toxicity was manageable with standard approaches.[1] The study was presented on November 11, 2016 at the 2016 Best of ASTRO meeting, a two-day summary of the ASTRO Annual Meeting, at which the most relevant and practice-changing abstracts are presented. "For patients newly diagnosed with SPB, this study could change the game. We now have hope that the patients with SBP can live without disease and without major side effects after treatment with new targeted agents in addition to precise radiation treatments," said Youlia M. Kirova, MD, senior radiation oncologist at the Curie Institute in Paris and investigator of the study. "Tolerance was excellent because of the TomoTherapy System's highly conformal dose distribution which enabled clinicians to deliver optimal doses of radiation while sparing healthy tissue and also because of the less toxic new targeted treatments." "This is a new approach enabling radiation oncologists, medical oncologists, and hematologists to give their patients prolonged progression-free survival (PFS)," Fabienne Hirigoyenberry-Lanson, PhD, vice president medical affairs, at Accuray. "These study results add to the evidence supporting the TomoTherapy System as an innovative and safe radiation therapy treatment for hemopathies such as hematological cancers.[1],[2]" SPB is a rare disease with a high rate of progression to multiple myeloma (MM). The role of systemic treatments given concurrently with radiation therapy was uncertain in SPB and had never been evaluated This study is the first to investigate whether patients who received a short course of IMiD or PI in addition to IMRT delivered with the TomoTherapy System had a longer progression free survival than patients treated only with IMRT. The study showed that: The study titled "Intensity Modulated Radiation Therapy by Tomotherapy (IMRT) Concurrent With a Short Systemic Treatment for Solitary Plasmacytoma of the Bone (SPB) With Improvement of Progression-Free Survival" (1) is a retrospective analysis of the medical and dosimetry records of 28 consecutive patients treated for SPB in the Department of Radiation Oncology at the Curie Institute between 2004 and 2013. All patients had histologically proven plasmacytoma of the bone, without bone marrow involvement. Fifteen patients received the standard treatment, 40 Gy radiotherapy, and 13 patients received treatment with IMiDs or PIs, in addition to the 40 Gy radiotherapy delivered by IMRT. For Important Safety Information please refer to http://www.accuray.com/safety-statement-radiationtreatment The Accuray TomoTherapy H™ Series efficiently enables physicians to customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for more optimal sparing of healthy tissue and critical structures. Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures, and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit http://www.accuray.com . Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 24, 2016, the company's report on Form 10-Q, filed on November 1, 2016, and as updated periodically with the company's other filings with the SEC. Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.


News Article | March 2, 2017
Site: www.prnewswire.co.uk

The Internet is one of the first places patients turn to for healthcare information after receiving a cancer diagnosis, according to the American Cancer Society. Accuray Incorporated (NASDAQ: ARAY) is launching http://www.cyberknife.com and http://www.tomotherapy.com to provide an additional resource for cancer patients to turn to for information about their disease and potential treatment options. Enhanced functionality and ease-of-use puts the information patients need at their fingertips. "Patients have told us they want concise information on potential treatment options that is easy to understand, and they want to hear from others who can share their real-world experiences," said Susan Hopkins, Chief Marketing Officer at Accuray. "We're committed to providing cancer patients with educational tools and resources which will enable them, in conversation with their physicians, to make the treatment decisions that are right for them. We are launching these new patient websites along with a major update to our Accuray.com website as well." The CyberKnife®, TomoTherapy® and Radixact™ Systems enable physicians to deliver precise, non-invasive radiation treatment options while minimizing side effects, helping to improve quality of life. The product websites feature a variety of resources, including: "Following successful treatment with the CyberKnife System for a tumor on my spine, I gained a new perspective on life. I want to help other people who, like me, are given a frightening diagnosis. In addition to volunteering, I decided to share my story on http://www.cyberknife.com," said Maria H. "The new website has the information I would want as a patient considering treatment, and is really easy to navigate. I feel good about sending people to the site and hope my story inspires others who find themselves in a similar situation." By 2030, the global cancer incidence rate is projected to reach 25 million[i]. Radiotherapy (RT) is a fundamental component of oncology care[ii] and an estimated 50% of cancer patients would benefit from radiotherapy for treatment of localized disease, local control, and palliation.[iii] "When my doctor diagnosed me with multiple myeloma I remember saying to myself, 'I refuse to die. I want to learn as much as I can about my condition.' Coming to grips with cancer is difficult but can be easier when advanced treatment options are identified. The Internet is an important resource for information that can help patients make a decision," said Carol R. "I recommend visiting the new tomotherapy.com website. It's filled with information a potential patient might need to help them, in discussion with their doctor, to decide if it's the right treatment for them. The patient stories, mine included, provide a real-world perspective on what to expect from a TomoTherapy® treatment." The Radixact™ Treatment Delivery System is the next generation TomoTherapy platform, designed to enable doctors to more efficiently and effectively deliver precise radiation treatments to more patients. The system offers doctors the opportunity to improve the cancer treatment experience throughout a patient's treatment journey, including when retreatment is necessary. About the CyberKnife®, TomoTherapy and Radixact™ Systems The Accuray CyberKnife M6™ Series, TomoTherapy H™ Series and Radixact treatment solutions cover the entire spectrum of radiation therapy needs. The CyberKnife M6 Series enables precise, high-quality, dose distributions to be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The CyberKnife System is the only robotic full-body radiosurgery system available today. The TomoTherapy H Series efficiently enables physicians to customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures. The Radixact System empowers clinicians by integrating treatment planning, data management and treatment delivery. Using low-dose fan beam megavoltage x-ray radiation, refined beamline and fast imaging technology, the system delivers scalable and highly reliable treatment for patients with a variety of treatment requirements. Further information on Accuray and the CyberKnife, TomoTherapy and Radixact Systems is available at http://www.accuray.com For Important Safety Information please refer to Accuray website. Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit http://www.accuray.com. Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 24, 2016, the company's reports on Form 10-Q, filed on November 1, 2016 and February 3, 2017, and as updated periodically with the company's other filings with the SEC. Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements. [i.] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-86. [iii.] Barton MB, Jacob S, Shafiq J, et al. Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. Radiother Oncol 2014; 112: 140-44.


Lu W.,TomoTherapy
Physics in Medicine and Biology | Year: 2010

We present a novel framework that enables very large scale intensity-modulated radiation therapy (IMRT) planning in limited computation resources with improvements in cost, plan quality and planning throughput. Current IMRT optimization uses a voxel-based beamlet superposition (VBS) framework that requires pre-calculation and storage of a large amount of beamlet data, resulting in large temporal and spatial complexity. We developed a non-voxelbased broad-beam (NVBB) framework for IMRT capable of direct treatment parameter optimization (DTPO). In this framework, both objective function and derivative are evaluated based on the continuous viewpoint, abandoning 'voxel' and 'beamlet' representations. Thus pre-calculation and storage of beamlets are no longer needed. The NVBB framework has linear complexities (O(N3)) in both space and time. The low memory, full computation and data parallelization nature of the framework render its efficient implementation on the graphic processing unit (GPU). We implemented the NVBB framework and incorporated it with the TomoTherapy treatment planning system (TPS). The new TPS runs on a single workstation with one GPU card (NVBB-GPU). Extensive verification/validation tests were performed in house and via third parties. Benchmarks on dose accuracy, plan quality and throughput were compared with the commercial TomoTherapy TPS that is based on the VBS framework and uses a computer cluster with 14 nodes (VBS-cluster). For all tests, the dose accuracy of these two TPSs is comparable (within 1%). Plan qualities were comparable with no clinically significant difference for most cases except that superior target uniformity was seen in the NVBBGPU for some cases. However, the planning time using the NVBB-GPU was reduced many folds over the VBS-cluster. In conclusion, we developed a novel NVBB framework for IMRT optimization. The continuous viewpoint and DTPO nature of the algorithm eliminate the need for beamlets and lead to better plan quality. The computation parallelization on a GPU instead of a computer cluster significantly reduces hardware and service costs. Compared with using the current VBS framework on a computer cluster, the planning time is significantly reduced using the NVBB framework on a single workstation with a GPU card. © 2010 Institute of Physics and Engineering in Medicine.


Patent
TomoTherapy | Date: 2013-01-11

A dose calculation tool operable to generate a variance map that represents a dose uncertainty. The variance map illustrates on a point-by-point basis where high uncertainty in the dose may exist and where low uncertainty in the dose may exist. The dose uncertainty is a result of an error in one or more data parameters related to a delivery parameter or a computational parameter.


Patent
TomoTherapy | Date: 2010-08-31

A patient support device of a radiation therapy treatment system includes an electromechanical motor and control system for moving the support device. The control system utilizes regenerative braking concepts, converting the motor into a generator as the support device is moved such that no matter the load, the support device will be moved at a constant speed. The control system also allows for moving of the support device in the powered off situation (i.e., when there is no power to the support device).


SUNNYVALE, California, April 23, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that the company will highlight new CyberKnife® and TomoTherapy® technologies at the European Society for Therapeutic Radiology and Oncology (ESTRO) meeting, booth #2100, in Barcelona, Spain, April 24 – 27, 2015. The CyberKnife and TomoTherapy Systems are used to treat cancerous and benign tumors throughout the body. Each system precisely targets the tumor, delivering the prescribed radiation dose, while minimizing exposure to nearby healthy organs and tissues. At ESTRO, Accuray will showcase: For more information please visit Accuray website. The new Delivery Analysis Software for the TomoTherapy System Delivery Analysis for the TomoTherapy System recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA), in conjunction with the CE Mark in the European Union. The Delivery Analysis software is an innovative tool that leverages the unique architecture of the TomoTherapy System to provide unprecedented access to treatment delivery information. The software provides enhanced confidence in system performance before each treatment, and actionable insights to help ensure all treatments stay on track. A pre-treatment test of the multileaf collimator (MLC) checks for differences between expected and measured MLC performance using pulse-by-pulse detector signals. Additionally, an in-treatment analysis of each delivered fraction is generated from exit detector data. It allows physicians to see if a particular fraction was not delivered as expected and helps to clarify the nature of the issue that led to the dose miss observed. An enhanced Synchrony® Respiratory Tracking System for the CyberKnife System The Synchrony System is the only clinically proven system that uses continual image guidance to automatically adjust the movement of the beam in synchronization with movement of the target volume. This new technology enables clinicians to: Satellite Symposium: "Radiation Therapy: Connecting History, Innovation and Patients" The symposium will be held on Saturday, 25 April 2015 from 13:15 to 14:30, room 111 (level 1). Presentations will explore the progress that has been made over the last 30 years in radiation therapy and discuss Accuray's contribution to setting the standard for the precise treatments that are used today and will be used in the future. Chaired by Prof. Jurgen Peter Debus, M.D., Ph.D., Managing Director of the Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany, Symposium speakers will include: Dr. Cary Adams, CEO, the Union for International Cancer Control (UICC) and Chair of the NCD Alliance in Geneva, Switzerland; Prof. Ben J.M. Heijmen, Ph.D., Head of the Section of Medical Physics, Department of Radiation Oncology, Erasmus Medical Center, Rotterdam, The Netherlands; and Prof. Thomas Rockwell Mackie, Ph.D., Emeritus Professor, Departments of Medical Physics and Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, USA. About Accuray Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. Safe Harbor Statement Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes and Accuray's leadership position in and future contributions to radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 29, 2014, the company's reports on Form 10-Q, filed on November 7, 2014 and February 6, 2015, and the company's other filings with the SEC. Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.


10-Year Anniversary of First Total Marrow Irradiation Delivery with the TomoTherapy® System Illustrates Growing Impact of Groundbreaking Approach This month marks the 10-year anniversary of the first successful total marrow irradiation (TMI) using the TomoTherapy® System. This procedure was performed at City of Hope in Duarte, California. As a result of continuing research and use of the system for TMI, numerous centers around the world have adopted the approach, once considered to be impossible because of limitations inherent to conventional radiation therapy systems. TMI is an advanced form of total body irradiation, which has traditionally been an important part of bone marrow transplants (BMT). People with certain types of cancers or other diseases including leukemias, lymphomas and multiple myeloma may undergo a BMT as part of their treatment. Before the transplant, chemotherapy and/or radiation may be given to neutralize any cancer in the marrow. Traditional approaches to total body irradiation resulted in the same dose of radiation delivered to the entire body, not just the bone marrow, causing damage to healthy organs and side effects ranging from nausea and diarrhea to cataracts and secondary malignancies. In contrast, the TomoTherapy System delivers small radiation "beamlets" from 360 degrees around the patient, allowing for greater control of the prescription dose so it conforms precisely to the target. This enables physicians to irradiate the bone marrow with larger doses of radiation while sparing nearby normal, healthy organs and limiting radiation side effects. Also, the system's CT scanner-based design allows efficient delivery of radiation to very large areas without field matching. These attributes are unique to the TomoTherapy System and facilitate its use for TMI as an alternative to total body irradiation. The TomoTherapy System is the only radiation system specifically designed for image-guided intensity-modulated radiation therapy (IMRT). More than 950 scientific articles have been published on TomoTherapy technology, with many addressing the clinical value and patient benefit of this treatment modality across a broad range of indications. The system offers clinicians the flexibility to deliver treatment in a helical mode or from clinician-specified beam angles with TomoDirect™ Mode. These unique features, combined with daily 3D image guidance, enable physicians to: Joshua H. Levine, president and chief executive officer of Accuray: "The TomoTherapy® System is a radiotherapy technology that allows entirely new approaches, while also bringing the highest quality care to the widest range of patients. In honor of National Cancer Survivor's Day, June 7, 2015, we want to recognize the clinicians worldwide who are using technologies such as the TomoTherapy System to improve the way cancer is managed and bring new hope to people who previously would have been without options." Dr. Stefano Vagge, MD, Ph.D: "The A.O.U. IRCCS San Martino IST National Cancer Research Institute of Genoa is dedicated to using innovative technologies to help cancer patients. Six years ago we tried to set a new standard of care in Europe when we began using the TomoTherapy System for TMI, an innovative approach that has become a critical part of our practice. We have treated more than fifty patients in the setting of autologous and allogenic stem cell transplantation for high-risk leukemia, lymphoma and multiple myeloma. In our clinical experience, the TomoTherapy System allows us to work collaboratively with the Genoa Hematopoietic Stem Cell Transplantation Department, a vanguard in Europe, to significantly reduce radiation toxicity and implement new treatment approaches in hematology." The Accuray TomoTherapy System enables physicians to efficiently customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures. Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit http://www.accuray.com. Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes and Accuray's leadership position in and future contributions to radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 29, 2014, the company's reports on Form 10-Q, filed on November 7, 2014, February 6, 2015 and May 7, 2015, and the company's other filings with the SEC. Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Loading TomoTherapy collaborators
Loading TomoTherapy collaborators